Picture loading failed.

Anti-PCSK9 therapeutic antibody (Pre-made Alirocumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-016-1mg 1mg 3090
GMP-Bios-ab-016-10mg 10mg 21890
GMP-Bios-ab-016-100mg 100mg 148000
GMP-Bios-ab-016-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-PCSK9 therapeutic antibody (Pre-made Alirocumab biosimilar,Whole mAb)
INN Name Alirocumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesRegeneron Pharmaceuticals;Sanofi;University Hospital Inselspital
Conditions ApprovedHypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias
Conditions ActiveCoronary artery disease
Conditions Discontinuedna
Development TechVelocImmune Mouse